Company intelligence / Profile preview

Scinvivo

Ownership: Private
Development stage: Preclinical

Overview

Scinvivo has developed a minimally invasive forward-looking OCT catheter and associated software to provide real-time, ultra-high-resolution images of tissue structures below the surface during cystoscopy. The technology aims to improve early diagnosis and monitoring of bladder cancer by enabling differentiation between non-invasive and muscle-invasive disease stages. Clinical validation and regulatory approvals are still pending

Therapeutic areas: Oncology
Modalities: DeviceOptical Coherence Tomography [OCT] catheter
Industry: Medical Imaging

Partnerships

NLC Health VenturesNetherlands Enterprise Agency/RVOSantec CorporationNextStageNOM

Beyond the preview

Go deeper on Scinvivo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scinvivo.

Explore the full profile